David Malcom Rodman
Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $14.4M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 12SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 2,17051,384 held (−4%) | $27.09 | $59K | -13.7% |
| Jul 20SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 41651,384 held (−1%) | $26.53 | $11K | -11.9% |
| Jul 15SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 14,05857,733 held (−20%) | $27.58 | $388K | -15.3% |
| Jul 15SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 6,34951,384 held (−11%) | $26.61 | $169K | -12.2% |
| Jul 10SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 2,17157,733 held (−4%) | $30.30 | $66K | -22.9% |
| Jun 17SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 9,89057,095 held (−15%) | $23.81 | $235K | -1.8% |
| Jun 17SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 4,58457,095 held (−7%) | $25.00 | $115K | -6.5% |
| Jun 12SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 2,17063,443 held (−3%) | $25.00 | $54K | -6.5% |
| Jun 12SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 6,34963,443 held (−9%) | $23.93 | $152K | -2.3% |
| May 19SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 41763,443 held (−1%) | $27.55 | $11K | -15.2% |
| May 13SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 2,17169,792 held (−3%) | $29.71 | $65K | -21.3% |
| May 13SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 6,34869,792 held (−8%) | $29.36 | $186K | -20.4% |
| May 13SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 14,05663,443 held (−18%) | $28.58 | $402K | -18.2% |
| Apr 21SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 41669,792 held (−1%) | $31.33 | $13K | -25.4% |
| Apr 15SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 14,05876,140 held (−16%) | $26.54 | $373K | -11.9% |
| Apr 15SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 6,34869,792 held (−8%) | $27.66 | $176K | -15.5% |
| Apr 13SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 2,17076,140 held (−3%) | $27.38 | $59K | -14.6% |
| Mar 17SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 41776,140 held (−1%) | $25.65 | $11K | -8.9% |
| Mar 16SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 6,34882,489 held (−7%) | $27.37 | $174K | -14.6% |
| Mar 16SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 10,72679,472 held (−12%) | $25.91 | $278K | -9.8% |
| Mar 16SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 3,07976,393 held (−4%) | $27.37 | $84K | -14.6% |
| Mar 16SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 25376,140 held (−0%) | $27.82 | $7K | -16.0% |
| Mar 10SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 2,17182,489 held (−3%) | $26.84 | $58K | -12.9% |
| Feb 17SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 41744,089 held (−1%) | $27.59 | $12K | -15.3% |
| Feb 13SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 5,82850,958 held (−10%) | $28.94 | $169K | -19.2% |
| Feb 13SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 52150,437 held (−1%) | $29.64 | $15K | -21.2% |
| Feb 13SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 3,54150,437 held (−7%) | $27.33 | $97K | -14.5% |
| Feb 13SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 4,16650,437 held (−8%) | $27.33 | $114K | -14.5% |
| Feb 13SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 6,34844,089 held (−13%) | $27.58 | $175K | -15.3% |
| Feb 11SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 2,17150,437 held (−4%) | $30.21 | $66K | -22.6% |
| Jan 20SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 41650,437 held (−1%) | $32.10 | $13K | -27.2% |
| Jan 15SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 7,70961,804 held (−11%) | $32.75 | $252K | -28.6% |
| Jan 15SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 11,36750,437 held (−18%) | $32.61 | $371K | -28.3% |
| Jan 13SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 2,17061,804 held (−3%) | $33.27 | $72K | -29.8% |
| Jan 13SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 6,34861,804 held (−9%) | $32.32 | $205K | -27.7% |
| Jan 6SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 70,03769,188 held (−50%) | $35.87 | $2.5M | -34.8% |
| Jan 6SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 139,245115,274 held (−55%) | $34.83 | $4.8M | -32.9% |
| Jan 6SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 53,47061,804 held (−46%) | $35.53 | $1.9M | -34.2% |
| Oct 15SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 10,36971,155 held (−13%) | $43.01 | $446K | -45.7% |
- Sell
Chief Medical Officer David Malcom Rodman sold $59K of MLYS at $27.09 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer David Malcom Rodman sold $11K of MLYS at $26.53 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer David Malcom Rodman sold $388K of MLYS at $27.58 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer David Malcom Rodman sold $169K of MLYS at $26.61 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer David Malcom Rodman sold $66K of MLYS at $30.30 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer David Malcom Rodman sold $235K of MLYS at $23.81 — pre-scheduled 10b5-1 plan sale.